(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Drugmakers will offer Eliquis at a 43% discount to uninsured U.S. patients, bypassing insurers and PBMs New $346 monthly ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...